STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
Bhakti Patel,Yifan Zhou,Rachel L. Babcock,Feiyang Ma,M. Anna Zal,Dhiraj Kumar,Yusra B. Medik,Laura M. Kahn,Josué E. Pineda,Elizabeth M. Park,Sarah M. Schneider,Ximing Tang,Maria Gabriela Raso,Collene R. Jeter,Tomasz Zal,Karen Clise-Dwyer,Khandan Keyomarsi,Filippo G. Giancotti,Simona Colla,Stephanie S. Watowich
DOI: https://doi.org/10.1038/s41375-024-02218-6
2024-03-12
Leukemia
Abstract:Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3 -deficiency in the hematopoietic compartment induces systemic inflammation, which can impact HSPC activity. Here, we developed mixed bone marrow (BM) chimeric mice with inducible Stat3 deletion in 20% of the hematopoietic compartment to avoid systemic inflammation. Stat3 -deficient HSPCs were significantly impaired in reconstitution ability following primary or secondary bone marrow transplantation, indicating hematopoietic stem cell (HSC) defects. Single-cell RNA sequencing of Lin − ckit + Sca1 + BM cells (LSKs) revealed aberrant activation of cell cycle, p53, and interferon (IFN) pathways in Stat3 -deficient HSPCs. Stat3 -deficient LSKs accumulated γH2AX and showed increased expression of DNA sensors and type-I IFN (IFN-I), while treatment with A151-ODN inhibited expression of IFN-I and IFN-responsive genes. Further, the blockade of IFN-I receptor signaling suppressed aberrant cell cycling, STAT1 activation, and nuclear p53 accumulation. Collectively, our results show that STAT3 inhibits a deleterious autocrine IFN response in HSCs to maintain long-term HSC function. These data signify the importance of ensuring therapeutic STAT3 inhibitors are targeted specifically to diseased cells to avoid off-target loss of healthy HSPCs.
oncology,hematology